Rashtriya Newsflash

DelveInsight’s “Autism Spectrum Disorders Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Autism Spectrum Disorders, historical and forecasted epidemiology as well as the Autism Spectrum Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Autism Spectrum Disorders market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Autism Spectrum Disorders Market Forecast

Some of the key facts of the Autism Spectrum Disorders Market Report:

• The Autism Spectrum Disorders market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In February 2026, Jaguar Gene Therapy, LLC, a clinical-stage biotechnology company focused on advancing gene therapy solutions for patients with severe genetic disorders—including those affecting large populations—announced that it has completed dosing for Cohort 1 in its first-in-human clinical study. The trial is assessing the safety, tolerability, and clinical activity of JAG201 in patients with SHANK3 haploinsufficiency, a key monogenic cause of autism spectrum disorder commonly diagnosed as Phelan-McDermid syndrome. Additionally, the first two participants in the dose-escalation Cohort 2 have received treatment, and the company expects to complete enrollment and dosing for this cohort in the second quarter of 2026. So far, no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) have been observed. Early signs of clinical improvement have been noted across several neurodevelopmental areas, including communication, motor skills, cognition, and social interaction.

• In May 2025, Yamo Pharmaceuticals, a clinical-stage biopharma company focused on addressing the core symptoms of autism spectrum disorder (ASD), announced encouraging Phase II results for its candidate L1-79. The findings were shared at the 2025 Annual Meeting of the International Society for Autism Research (INSAR). In a 12-week, randomized, double-blind, placebo-controlled crossover study involving 58 participants aged 12 to 21, L1-79 demonstrated statistically significant and clinically meaningful improvements in the Vineland-3 Socialization Standard Score (VSSS) and multiple secondary outcomes during the first treatment period, all while maintaining a favorable safety profile.

• In February 2025, Charlotte’s Web Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Phase I data and Investigational New Drug (IND) application submitted by DeFloria, Inc. Following the review, the FDA has authorized DeFloria to move forward with its planned Phase II clinical trial of AJA001 Oral Solution, a botanical drug candidate intended to treat symptoms associated with autism spectrum disorder (ASD).

• In January 2025, The Israeli Medical Cannabis Agency (IMCA) under the Ministry of Health renewed SciSparc’s clinical trial of SCI-210 for treating pediatric patients with autism spectrum disorder (ASD). This renewal is essential to ensure the study’s continuation while complying with IMCA’s regulatory standards.

• In July 2024, Jaguar Gene Therapy, a clinical-stage biotechnology company advancing gene therapy for severe genetic diseases affecting large patient populations, announced it has received U.S. Food and Drug Administration (FDA) feedback from a Type C meeting. The discussion focused on the Phase I clinical trial for JAG201, a gene replacement therapy targeting a genetic form of autism spectrum disorder (ASD) associated with SHANK3 mutations or deletions, as well as Phelan-McDermid syndrome.

• According to the analysis, approximately 1 in 44 eight-year-old children in the US are diagnosed with autism spectrum disorder, with boys being nearly four times more likely to receive a diagnosis compared to girls.

• Different sources suggest that nearly 700,000 individuals in the UK are diagnosed with autism, and about 1 in every 100 children has autism spectrum disorder.

• According to the analysis, in Germany, children aged 6 to 11 years exhibited the highest prevalence, estimated at roughly 6.0 per 1,000.

• The US Centers for Disease Control and Prevention (CDC) (2022) reports that 23.0 out of every 1,000 8-year-olds, or almost 1 in 44 children, have been diagnosed with Autism Spectrum Disorders. It was discovered that boys were four times more likely than girls to be diagnosed with Autism Spectrum Disorders.

• The British Medical Association (2020) estimates that 700,000 or so people in the UK are thought to be diagnosed with autism. In the UK, ASD is diagnosed in one out of every 100 youngsters

• In November 2021, a group of Indian researchers developed a compound called “6BIO” that can provide a better method to treat Autism Spectrum Disorder (ASD). They have determined the potency of the compound in a pre-clinical mice model. This is the first compound that has been proved in pre-clinical evaluation to have the potential for improving daily activities like learning and recollecting new tasks in patients with ASD/ Intellectual disability (ID).

• In October 2021, Axial Therapeutics obtained funding for a Phase II autism trial with USD 37 million Series C to further work on neurological diseases.

• Key Autism Spectrum Disorders Companies: Scioto Biosciences, Hoffmann-La Roche, Yamo Pharmaceutical, Jazz Pharmaceuticals, Axial Therapeutics, Eli Lilly and Company, AbbVie, and others

• Key Autism Spectrum Disorders Therapies: SB-121, RO6953958, L1-79, JZP541, AB-2004, Tasimelteon, Cariprazine, and others

• The Autism Spectrum Disorders epidemiology based on gender analyzed that Autism Spectrum Disorders is four times more common among boys than among girls

• The Autism Spectrum Disorders market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Autism Spectrum Disorders pipeline products will significantly revolutionize the Autism Spectrum Disorders market dynamics.

Autism Spectrum Disorders Overview

Autism Spectrum Disorders (ASD) are a group of neurodevelopmental conditions that affect communication, social interaction, behavior, and learning. People with ASD may have difficulty understanding social cues, engaging in conversations, or forming relationships. They often display repetitive behaviors, restricted interests, and may be sensitive to sounds, lights, or textures. Symptoms can range from mild to severe, which is why it is called a “spectrum.” ASD usually appears in early childhood and continues throughout life. While there is no cure, early intervention with therapies, behavioral support, and educational programs can significantly improve skills, independence, and quality of life.

Get a Free sample for the Autism Spectrum Disorders Market Report

https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

Autism Spectrum Disorders Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Autism Spectrum Disorders Epidemiology Segmentation:

The Autism Spectrum Disorders market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Autism Spectrum Disorders

• Prevalent Cases of Autism Spectrum Disorders by severity

• Gender-specific Prevalence of Autism Spectrum Disorders

• Diagnosed Cases of Episodic and Chronic Autism Spectrum Disorders

Download the report to understand which factors are driving Autism Spectrum Disorders epidemiology trends @ Autism Spectrum Disorders Epidemiology Forecast

Autism Spectrum Disorders Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autism Spectrum Disorders market or expected to get launched during the study period. The analysis covers Autism Spectrum Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Autism Spectrum Disorders Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Autism Spectrum Disorders Therapies and Key Companies

• SB-121: Scioto Biosciences

• RO6953958: Hoffmann-La Roche

• L1-79: Yamo Pharmaceutical

• JZP541: Jazz Pharmaceuticals

• AB-2004: Axial Therapeutics

• Tasimelteon: Eli Lilly and Company

• Cariprazine: AbbVie

Discover more about therapies set to grab major Autism Spectrum Disorders market share @ Autism Spectrum Disorders Treatment Market

Scope of the Autism Spectrum Disorders Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Autism Spectrum Disorders Companies: Scioto Biosciences, Hoffmann-La Roche, Yamo Pharmaceutical, Jazz Pharmaceuticals, Axial Therapeutics, Eli Lilly and Company, AbbVie, and others

• Key Autism Spectrum Disorders Therapies: SB-121, RO6953958, L1-79, JZP541, AB-2004, Tasimelteon, Cariprazine, and others

• Autism Spectrum Disorders Therapeutic Assessment: Autism Spectrum Disorders current marketed and Autism Spectrum Disorders emerging therapies

• Autism Spectrum Disorders Market Dynamics: Autism Spectrum Disorders market drivers and Autism Spectrum Disorders market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Autism Spectrum Disorders Unmet Needs, KOL’s views, Analyst’s views, Autism Spectrum Disorders Market Access and Reimbursement

To know more about Autism Spectrum Disorders companies working in the treatment market, visit @ Autism Spectrum Disorders Clinical Trials and Therapeutic Assessment

Table of Contents

1. Autism Spectrum Disorders Market Report Introduction

2. Executive Summary for Autism Spectrum Disorders

3. SWOT analysis of Autism Spectrum Disorders

4. Autism Spectrum Disorders Patient Share (%) Overview at a Glance

5. Autism Spectrum Disorders Market Overview at a Glance

6. Autism Spectrum Disorders Disease Background and Overview

7. Autism Spectrum Disorders Epidemiology and Patient Population

8. Country-Specific Patient Population of Autism Spectrum Disorders

9. Autism Spectrum Disorders Current Treatment and Medical Practices

10. Autism Spectrum Disorders Unmet Needs

11. Autism Spectrum Disorders Emerging Therapies

12. Autism Spectrum Disorders Market Outlook

13. Country-Wise Autism Spectrum Disorders Market Analysis (2020–2034)

14. Autism Spectrum Disorders Market Access and Reimbursement of Therapies

15. Autism Spectrum Disorders Market Drivers

16. Autism Spectrum Disorders Market Barriers

17. Autism Spectrum Disorders Appendix

18. Autism Spectrum Disorders Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/